We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Blocking a Long Noncoding RNA Reduces Stroke Damage in Rat Model

By LabMedica International staff writers
Posted on 29 Dec 2015
By preventing expression of a long noncoding RNA (lncRNA) following induced stroke in a rat model, neurosciences researchers were able to limit damage to the brain and reduce the severity of post-stroke symptoms.

Long noncoding RNAs (lncRNAs) are non-protein coding transcripts longer than 200 nucleotides. More...
This somewhat arbitrary limit distinguishes lncRNAs from small regulatory RNAs such as microRNAs (miRNAs), short interfering RNAs (siRNAs), Piwi-interacting RNAs (piRNAs), small nucleolar RNAs (snoRNAs), and other short RNAs. LncRNAs have been found to be involved in numerous biological roles including imprinting, epigenetic gene regulation, cell cycle and apoptosis, and metastasis and prognosis in solid tumors. Most lncRNAs are expressed only in a few cells rather than whole tissues, or they are expressed at very low levels, making them difficult to study.

In addition to protein-coding RNAs, many classes of noncoding RNAs, including lncRNAs, undergo changes in the brain following a stroke. To better understand the roll of non-coding RNAs in stroke, investigators at the University of Wisconsin-Madison (USA) evaluated the functional significance of an lncRNA called FosDT (Fos downstream transcript) that is coded on the same chromosome as the FOS gene (FBJ murine osteosarcoma viral oncogene homolog). The FOS proteins have been implicated as regulators of cell proliferation, differentiation, and transformation. In some cases, expression of the FOS gene has also been associated with apoptotic cell death.

In the current study, ischemic stroke was induced in laboratory rats by blocking an artery in the brain for one hour. Some of the animals were treated with anti-sense RNA that blocked the production of the lncRNA FosDT.

Results published in the December 16, 2015, issue of the Journal of Neuroscience revealed that stroke induced production of FOS and FosDT in the untreated animals. In the treated animals FosDT knockdown significantly ameliorated post-ischemic motor deficits and reduced the infarct volume. These effects of FosDT in part were due to its interactions with chromatin-modifying proteins Sin3a and coREST (corepressors of the transcription factor REST) and subsequent derepression of REST-downstream genes GRIA2, NFkappaB2, and GRIN1.

"Stroke influences the expression of all types of RNA, and this RNA has a broad influence throughout the cell after the blood supply is restored, in what we call reperfusion injury," said senior author Dr. Raghu Vemuganti, professor of neurological surgery at the University of Wisconsin-Madison. "A few years ago, our lab started to look at how stroke affects noncoding RNA. Two years ago, we identified about 200 types of various lncRNAs that greatly increase or decrease after stroke, and zeroed in on one that we named FosDT. We knew that the level of FosDT went up more than tenfold in the rat brain within three hours after the stroke. We thought, if we block FosDT after the stroke, would it make any difference in the amount of structural damage or behavioral disability?"

"We did not change the initial insult, caused by lack of oxygen," said Dr. Vemuganti, "but this targeted approach greatly reduced the damage after one week. We cannot completely reverse the post-stroke damage, but the total damage decreased by one-third. If we can protect this much brain tissue from stroke, that would be an enormous improvement."

Related Links:

University of Wisconsin-Madison



New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated Biochemical Analyzer
iBC 900
New
Silver Member
Autoimmune Hepatitis Test
LKM-1-Ab ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.